Crossbow raises Series A funds to develop cancer antibodies

12 Jul 2023
www.pharmaceutical-technology.com
VaccineImmunotherapy
Crossbow raises Series A funds to develop cancer antibodies
Preview
Source: Pharmaceutical Technology
Crossbow Therapeutics will use the funds to develop therapies to treat cancer. Credit: crystal light via Shutterstock.com.
Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer.
MPM BioImpact and Pfizer Ventures led the funding round, with Polaris Partners, BVF Partners and Eli Lilly and Company among others taking part.
Recommended Reports
Crossbow raises Series A funds to develop cancer antibodies
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vaccine For Oncology in Colorectal Cancer GlobalData
Crossbow raises Series A funds to develop cancer antibodies
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy To Target Lewis Y Antigen For Lung Cancer in Lung Cancer GlobalData
View allCompanies IntelligenceEli Lilly and CoPolaris Partners LLCBVF Partners LPCrossbow CorpPfizer Ventures LLCView all
Proceeds will be used to progress the development of new therapies that act on peptide-loaded major histocompatibility complexes (pMHCs) present on cancer cells.
To target pMHCs, these therapies will leverage antibodies that imitate T-cell receptors (TCR-mimetics).
The company will identify, validate and select the most promising cancer-specific targets, then create TCR-mimetic antibodies that have greater levels of cancer cell affinity and specificity.
Such TCR-mimetics will be merged with off-the-shelf T-cell engagers and immunotherapies to create tumour-bolt (T-Bolt) molecules.
These T-Bolts can be tailored to treat a variety of cancers.
Crossbow Therapeutics CEO Briggs Morrison stated: “With unparalleled accuracy and potency, our revolutionary T-Bolt products strike cancer cells like a crossbow shoots bolts at its target.
“The influx of additional capital enables us to scale our efforts to build an arsenal of TCR-mimetic-based immunotherapies designed to overcome the limitations of current treatments.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.